Experimental evidence shows that genetic knockout of PKCβII or ACSL4, or site‐specific mutation blocking ACSL4 phosphorylation, significantly suppresses ferroptosis and T cell‐mediated tumor immune killing, ultimately driving resistance to PD‐1 inhibitor therapy [575]. The gene discussed is ACSL4; the disease is neoplasm.